Viewing StudyNCT05722418

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 6:36 PM
Last Modification Date: 2024-10-26 @ 2:51 PM
Study NCT ID: NCT05722418
Status: RECRUITING
Last Update Posted: 2024-05-06
First Post: 2022-12-19
Brief Title: CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With RelapsedRefractory Multiple Myeloma
Sponsor: Caribou Biosciences Inc
Organization: Caribou Biosciences Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
RelapsedRefractory Multiple Myeloma
Keywords:
Name View
Allogeneic View
Multiple Myeloma View
CAR-T Cells View
BCMA View
Cell Therapy View
CB11A View
CB-011A View
CAR-T View
Anti BCMA View
ALLO CAR T View
CaMMouflage View
Relapse Refractory Multiple Myeloma View
Cellular Immuno-therapy View
CB-011 View